Healthcare Professionals - Chiesi Total Care

Alicia, actual Ferriprox patient

One-stop patient support

Chiesi Total Care℠ is a comprehensive support program that provides exceptional service for you and your patients.

A single call to your dedicated Chiesi Total Care team is all it takes, and we will guide you through the process of getting a patient started on Ferriprox^® (deferiprone) therapy.^†

Call toll free: 1-866-758-7071

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.
Interrupt Ferriprox if infection develops and monitor the ANC more frequently.
Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.

Please see full Prescribing Information, including boxed WARNING and Medication Guide.

The Chiesi Total Care Program assists with:

Commercial Insurance

If your patients have private insurance through their job or their own business.

Government insurance

If your patients have Medicare, Medicaid, Veterans Affairs Healthcare, or other similar government insurance.

No insurance

If your patients have no insurance, they may be eligible for additional financial assistance.

The dedicated Total Care team is made up of:

Pharmacists
Patient service coordinators
Reimbursement support specialists
Nursing support

Worry-free refills

A pharmacist is always available and medication is delivered right to your patient’s door.

The Ferriprox Copay Program

For commercially insured patients:

Most patients pay as little as $0 per month
Up to $10,000 in out-of-pocket fees are covered annually

The Copay Program is available to patients subject to eligibility. Patients can learn about the Copay Program by calling the same Chiesi Total Care toll-free number.

1-866-758-7071^‡

Call the toll-free number to determine eligibility and learn terms and conditions.

Restrictions apply.

† Chiesi Total Care provides assistance to patients with or without commercial insurance, Medicaid, and Medicare.

‡ Not valid for patients with health coverage under Medicaid, Medicare, or any other federal or state program. Copay Program subject to further terms and conditions. Call the Chiesi Total Care team for complete Copay Program terms and conditions.

Access to Medication

Contact

Phone

866-758-7071
Fax

866-565-7794
Hours of Operation

Monday to Friday

7:00am – 6:00pm (Central Time)
Location

17877 Chesterfield Airport Road

Chesterfield, MO 36005

Helpful links for your patients

Cooley’s Anemia Foundation www.thalassemia.org
US Department of Health & Human Services, National Institutes of Health
https://rarediseases.info.nih.gov/guides/pages/120/support-for-patients-and-families
Patient Advocate Foundation www.patientadvocate.org
Patient Advocate Foundation Co-Pay Relief https://www.copays.org
HealthWell Foundation https://www.healthwellfoundation.org

Ferriprox (deferiprone) Tablets
Ferriprox (deferiprone) Oral Solution (100 mg/mL)
- Oral Solution PI
- Oral Solution Medication Guide

Safety Information

Indication

Ferriprox^® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival.

Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.

Important Safety Information

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor weekly while on therapy.
Interrupt Ferriprox if infection develops and monitor the ANC more frequently.
Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.

Ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulation.

In clinical studies, 7.5% of 642 patients treated with deferiprone developed increased ALT values. Four (0.62%) deferiprone-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. Monitor serum ALT values monthly during therapy with Ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels. Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc, and supplement in the event of a deficiency.

Ferriprox can cause fetal harm. Advise females of reproductive potential to use an effective method of contraception during treatment with Ferriprox and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Ferriprox and for at least three months after the last dose. Advise females not to breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Avoid co-administration of Ferriprox with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of Ferriprox and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

The most common adverse reactions are (incidence ≥5%) nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia, and neutropenia.

Inform patients that their urine might show a reddish/brown discoloration due to the excretion of iron. This is a very common sign of the desired effect, and it is not harmful.

Advise patients to avoid alcohol while taking Ferriprox tablets (twice-a-day). Consumption of alcohol while taking Ferriprox tablets (twice-a-day) may result in more rapid release of deferiprone.